Literature DB >> 1654309

Characterization of a murine model of recurrent herpes simplex viral keratitis induced by ultraviolet B radiation.

K A Laycock1, S F Lee, R H Brady, J S Pepose.   

Abstract

The authors characterized a murine model of herpes simplex virus (HSV) reactivation in which recurrent herpetic keratitis was obtained in up to 80% of animals. Five weeks after ganglionic latency was established in National Institutes of Health inbred mice after corneal inoculation, HSV type 1 (HSV-1) was reactivated by irradiating the previously inoculated eye with ultraviolet (UV) light. Comparison of different UV wavelengths showed UVB to be optimal for reactivation, with peak viral recurrence being induced by a total exposure of approximately 250 mJ/cm2. Reactivated infectious virus generally began to appear in trigeminal ganglia 2 days postirradiation and was subsequently detectable in the cornea by both corneal swabbing and immunostaining for viral antigens. Two consecutive outbreaks of viral recurrence at the ocular surface were induced in selected animals by serial exposure to UVB. Advantages of this model over other models of recurrent keratitis are discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1654309

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  44 in total

1.  Prophylactic and therapeutic effects of human immunoglobulin on the pathobiology of HSV-1 infection, latency, and reactivation in mice.

Authors:  Sarat K Dalai; Lesley Pesnicak; Georgina F Miller; Stephen E Straus
Journal:  J Neurovirol       Date:  2002-02       Impact factor: 2.643

2.  Quantitative analysis of herpes simplex virus reactivation in vivo demonstrates that reactivation in the nervous system is not inhibited at early times postinoculation.

Authors:  N M Sawtell
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

3.  A 348-base-pair region in the latency-associated transcript facilitates herpes simplex virus type 1 reactivation.

Authors:  D C Bloom; J M Hill; G Devi-Rao; E K Wagner; L T Feldman; J G Stevens
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

4.  Social stress and the reactivation of latent herpes simplex virus type 1.

Authors:  D A Padgett; J F Sheridan; J Dorne; G G Berntson; J Candelora; R Glaser
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

5.  Decreased reactivation of a herpes simplex virus type 1 (HSV-1) latency-associated transcript (LAT) mutant using the in vivo mouse UV-B model of induced reactivation.

Authors:  Lbachir BenMohamed; Nelson Osorio; Ruchi Srivastava; Arif A Khan; Jennifer L Simpson; Steven L Wechsler
Journal:  J Neurovirol       Date:  2015-05-22       Impact factor: 2.643

Review 6.  Experimental investigation of herpes simplex virus latency.

Authors:  E K Wagner; D C Bloom
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

7.  Therapeutic immunization with a virion host shutoff-defective, replication-incompetent herpes simplex virus type 1 strain limits recurrent herpetic ocular infection.

Authors:  Tammie L Keadle; Lynda A Morrison; Jessica L Morris; Jay S Pepose; Patrick M Stuart
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

8.  The spread of herpes simplex virus type 1 from trigeminal neurons to the murine cornea: an immunoelectron microscopy study.

Authors:  P T Ohara; M S Chin; J H LaVail
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

9.  The herpes simplex virus type 1 ICP0 promoter is activated by viral reactivation stimuli in trigeminal ganglia neurons of transgenic mice.

Authors:  C M Loiacono; N S Taus; W J Mitchell
Journal:  J Neurovirol       Date:  2003-06       Impact factor: 2.643

10.  Lornoxicam suppresses recurrent herpetic stromal keratitis through down-regulation of nuclear factor-kappaB: an experimental study in mice.

Authors:  Jie Yin; Zhenping Huang; Yuan Xia; Fei Ma; Li Jing Zhang; Heng Hui Ma; Li Li Wang
Journal:  Mol Vis       Date:  2009-06-14       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.